Study Summary
This trial is testing a new, less invasive way to replace a failing tricuspid valve.
- Tricuspid Regurgitation
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Through 30 days post-procedure
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Primary Cohort
1 of 1
Experimental Treatment
15 Total Participants · 1 Treatment Group
Primary Treatment: Intrepid™ TTVR System · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
To what extent is enrollment in this research endeavor being facilitated?
"To begin the study, 15 eligible participants are necessary. Medtronic Cardiovascular will be managing the experiment from a variety of locations, such as Aurora Saint Luke's Medical in Milwaukee and Abrazo Arizona Heart Hospital in Phoenix." - Anonymous Online Contributor
In which areas can participants access this trial?
"Patients may find enrollment opportunities at 15 different sites, including Aurora Saint Luke's Medical in Milwaukee, Abrazo Arizona Heart Hospital in Phoenix and University of Alabama at Birmingham (UAB) Hospital in Birmingham." - Anonymous Online Contributor
Are there any available openings for participants in this clinical exploration?
"Affirmative. According to the information found on clinicaltrials.gov, this trial was first made available on October 20th 2020 and has been actively recruiting since then; as of November 21st 2022 it is still looking for 15 participants from 15 different locations." - Anonymous Online Contributor